Novartis, a Swiss pharmaceutical company, recently announced plans to invest $23 billion over the next five years in expanding its presence in the United States. This expansion includes the construction of six new factories, the expansion of three existing facilities, and the establishment of a new research and development hub. The goal of this investment is to enable Novartis to produce all medications intended for U.S. patients within the country, a move that aligns with President Donald Trump’s push for companies to bring manufacturing back to the U.S. in light of tariff policies impacting global trade.
Novartis’ investment follows similar initiatives by other pharmaceutical giants such as Eli Lilly, Merck & Co., and Johnson & Johnson, who have also announced plans to increase capital expenditures and manufacturing capabilities in the U.S. as a response to the current political and economic landscape. This move by Novartis represents a shift from its previous strategy of downsizing its operations in the U.S., including the closure of research and manufacturing sites in various states.
The expansion plan includes the construction of two new plants in Florida and Texas to manufacture radiopharmaceuticals, as well as the expansion of existing facilities in Indianapolis, New Jersey, and Carlsbad, California. Novartis also plans to establish four additional facilities to produce biologic and chemical drug substances, pills, and packaging. This investment will allow Novartis to bring some of its most complex and innovative drug manufacturing processes, such as cell and gene therapies, to the U.S. for the first time.
Additionally, Novartis will be investing in a $1.1 billion “biomedical research innovation hub” in San Diego, which is expected to be operational between 2028 and 2029. CEO Vas Narasimhan expressed confidence in the company’s ability to navigate trade disruptions and maintain its growth projections, citing a strong outlook for sales growth and core margins.
Overall, Novartis’ expansion in the U.S. represents a significant commitment to strengthening its manufacturing and research capabilities in the country, in line with the broader trend of reshoring and localization in response to global economic challenges. By investing in new facilities and technology platforms, Novartis aims to enhance its supply chain resilience and support its long-term growth objectives.
Related Analysis: View Previous Industry Report
